SCM
FATE icon

Silvant Capital Management’s Fate Therapeutics FATE Stock Holding History

Silvant Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,975
Closed -$89K – 314
2022
Q3 		$89K Hold
3,975
– – 0.01% 260
2022
Q2 		$99K Hold
3,975
– – 0.02% 209
2022
Q1 		$154K Hold
3,975
– – 0.03% 191
2021
Q4 		$233K Sell
3,975
-255
-6% -$14.5K 0.04% 171
2021
Q3 		$251K Hold
4,230
– – 0.04% 169
2021
Q2 		$367K Hold
4,230
– – 0.06% 144
2021
Q1 		$349K Hold
4,230
– – 0.06% 148
2020
Q4 		$385K Hold
4,230
– – 0.07% 147
2020
Q3 		$169K Buy
4,230
+1,436
+51% +$50.1K 0.03% 184
2020
Q2 		$96K Buy
+2,794
New +$83.3K 0.02% 216

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silvant Capital Management's FATE Position: Q4 2022 in Review

Silvant Capital Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 3,975 shares — an estimated $89K sold.

Silvant Capital Management first reported a position in FATE in Q2 2020 and held it in 10 quarters. The position peaked at $385K in Q4 2020. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Silvant Capital Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Silvant Capital Management sold 3,975 Fate Therapeutics shares in Q4 2022, an estimated $89K.
  • Silvant Capital Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 10 quarters.
  • Silvant Capital Management's Fate Therapeutics position peaked at $385K in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Silvant Capital Management's 13F filing for Q4 2022, filed 23 Jan 2023.